These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 36428727)

  • 1. Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints.
    Franzese O; Graziani G
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.
    Peyraud F; Italiano A
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32526888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors.
    Wu Z; Cui P; Tao H; Zhang S; Ma J; Liu Z; Wang J; Qian Y; Chen S; Huang Z; Zheng X; Huang D; Hu Y
    Clin Med Insights Oncol; 2021; 15():1179554921996288. PubMed ID: 33737855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system.
    Bound NT; Vandenberg CJ; Kartikasari AER; Plebanski M; Scott CL
    Front Genet; 2022; 13():886170. PubMed ID: 36159999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential of PARP inhibitors in targeted cancer therapy and immunotherapy.
    Hunia J; Gawalski K; Szredzka A; Suskiewicz MJ; Nowis D
    Front Mol Biosci; 2022; 9():1073797. PubMed ID: 36533080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
    Moutafi M; Economopoulou P; Rimm D; Psyrri A
    Oral Oncol; 2021 Jun; 117():105292. PubMed ID: 33862558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications.
    Wanderley CWS; Correa TS; Scaranti M; Cunha FQ; Barroso-Sousa R
    Front Immunol; 2022; 13():816642. PubMed ID: 35572596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment.
    Catalano M; Francesco Iannone L; Cosso F; Generali D; Mini E; Roviello G
    Expert Opin Ther Targets; 2022 Nov; 26(11):923-936. PubMed ID: 36519314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.
    Prasanna T; Wu F; Khanna KK; Yip D; Malik L; Dahlstrom JE; Rao S
    Cancer Sci; 2018 Nov; 109(11):3383-3392. PubMed ID: 30230653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer.
    Han Y; Li CW; Hsu JM; Hsu JL; Chan LC; Tan X; He GJ
    Am J Cancer Res; 2019; 9(4):800-815. PubMed ID: 31106005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in cancer therapy using PARP inhibitors.
    Kaur SD; Chellappan DK; Aljabali AA; Tambuwala M; Dua K; Kapoor DN
    Med Oncol; 2022 Sep; 39(12):241. PubMed ID: 36180646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
    Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
    J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances and perspectives of PARP inhibitors.
    Yi M; Dong B; Qin S; Chu Q; Wu K; Luo S
    Exp Hematol Oncol; 2019; 8():29. PubMed ID: 31737426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
    Chiappa M; Guffanti F; Bertoni F; Colombo I; Damia G
    Drug Resist Updat; 2021 Mar; 55():100744. PubMed ID: 33551306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advancements in PARP inhibitors-based targeted cancer therapy.
    Zhou P; Wang J; Mishail D; Wang CY
    Precis Clin Med; 2020 Sep; 3(3):187-201. PubMed ID: 32983586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
    Shen J; Zhao W; Ju Z; Wang L; Peng Y; Labrie M; Yap TA; Mills GB; Peng G
    Cancer Res; 2019 Jan; 79(2):311-319. PubMed ID: 30482774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
    Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
    [No Abstract]   [Full Text] [Related]  

  • 18. Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
    Chu YY; Yam C; Yamaguchi H; Hung MC
    J Biomed Sci; 2022 Oct; 29(1):86. PubMed ID: 36284291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
    Xiong J; Barayan R; Louie AV; Lok BH
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer.
    Xie Y; Xiao D; Li D; Peng M; Peng W; Duan H; Yang X
    Front Oncol; 2024; 14():1441222. PubMed ID: 39156700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.